biosimilars

[BLOG]: 5 things you need to know about biosimilarsThe first biosimilar product was approved this spring. Pharmacists will want to familiarize themselves with this new class of therapies. Below are the five top things that a pharmacist should know about biosimilars.
Study: Biosimilars may result in minimal savingsA recent study projects that U.S. employers may see minimal savings to overall healthcare costs resulting from the introduction of biosimilars to the U.S. market.
Biosimilars’ savings could be lower than predictedWhile biosimilars’ savings will not reach the historically high level achieved for small-molecule generic drugs, the impact on the healthcare industry will still be significant, according to a new report.
First biosimilar in U.S. now availableSandoz announced that Zarxio (filgrastim-sndz), the first biosimilar approved by the FDA in March, is now available in the United States.
Sandoz touts value of first biosimilar for cancerThe first biosimilar drug approved by FDA in March was officially launched in the United States on September 3 – at a value compared to competing medications.
Biosmilars’ naming proposal could cause “significant” changesPharmacies should be wary of potential drug name changes that could occur if FDA finalizes its new draft guidance on biosimilar naming, which proposes proper names for biosimilars.
Biosimilars and interchangeability: Many questions, few answersInterchangeability means different things to different stakeholders. Here are some things they will need to agree on.
The five forces that shape the biosimilar pipeline
The five forces that shape the biosimilar pipelineThe biosimilars pipeline is flush with new products, and it could be shortening. Here's why.
The market side of biosimilarsR&D and product manufacture are only the beginning. When the time comes to enter the marketplace, biosimilars still face numerous obstacles.
What’s holding up biosimilar development?Canada, the E.U., South Korea, Japan, India, and Australia — all have had clear regulatory pathways in place for years. The United States has been working on a biosimilars pathway for almost a decade. What's different?